(Q38085679)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Mehrdad Dirin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

2 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

875-888

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Nucleic acids as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Antisense drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Off-target effects related to the phosphorothioate modification of nucleic acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Morpholino antisense oligomers: the case for an RNase H-independent structural type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Gene knockdowns in adult animals: PPMOs and vivo-morpholinos

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

21 January 2018

Disposition of biologics

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Antisense treatment for myasthenia gravis: experience with monarsen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Oral delivery of siRNA and antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC/Nga mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux) technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Toxicology of antisense therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Biological barriers to therapy with antisense and siRNA oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Phosphorothioate-stimulated uptake of short interfering RNA by human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Life-or-death decisions by the Bcl-2 protein family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Cellular uptake of neutral phosphorodiamidate morpholino oligomers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Advanced morpholino oligomers: a novel approach to antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

A primer for morpholino use in zebrafish.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

In vivo drug discovery in the zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Phosphorothioate oligonucleotides block the VDAC channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Specific VDAC inhibitors: phosphorothioate oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

CpG DNA as a vaccine adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Morpholino artifacts provide pitfalls and reveal a novel role for pro-apoptotic genes in hindbrain boundary development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Delivery of siRNA therapeutics: barriers and carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Rational design of cationic lipids for siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Mipomersen as a potential adjunctive therapy for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Systemic administration of PRO051 in Duchenne's muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Small heat shock proteins in cancer therapy and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Akt inhibitors in clinical development for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

Liposomal antisense oligonucleotides for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.774366

10.1517/14712598.2013.774366

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23451977%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference